$STRO News

Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors

Sutro Biopharma Doses First Patient In Its Phase 1 Trial Of STRO-006 In Patients With Range Of Solid Tumors; Initial Clinical Data Expected In H2 2027

Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target

Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference

Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development

Citizens Maintains Market Outperform on Sutro Biopharma, Lowers Price Target to $34

Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target

STRO Stock Plummets 15% — What Drove The Selloff?

Why is Sutro Biopharma Stock Falling On Wednesday?

Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study

Sutro Biopharma Q2 EPS $(2.33) Misses $(2.19) Estimate, Sales $9.839M Miss $13.048M Estimate

Truist Securities Assumes Sutro Biopharma at Buy, Announces Price Target of $50

News Flash: Analysts Just Made A Massive Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Forecasts

Barclays Initiates Coverage On Sutro Biopharma with Overweight Rating, Announces Price Target of $56

US$47.10 - That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These Results

Leerink Partners Maintains Outperform on Sutro Biopharma, Raises Price Target to $43

Wedbush Upgrades Sutro Biopharma to Outperform, Raises Price Target to $60

HC Wainwright & Co. Maintains Buy on Sutro Biopharma, Raises Price Target to $50

Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights

Sutro Biopharma Q1 EPS $(2.94) Beats $(3.77) Estimate, Sales $14.523M Beat $8.079M Estimate